These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 17096336)

  • 21. HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions.
    Evans C; Bauer S; Grubert T; Brucker C; Baur S; Heeg K; Wagner H; Lipford GB
    Cancer Immunol Immunother; 1996 Mar; 42(3):151-60. PubMed ID: 8640843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HPV16 E6 29-38-specific T cells kill cervical carcinoma cells despite partial evasion of T-cell effector function.
    Thomas KJ; Smith KL; Youde SJ; Evans M; Fiander AN; Borysiewicz LK; Man S
    Int J Cancer; 2008 Jun; 122(12):2791-9. PubMed ID: 18366058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Roman JJ; Jayaprabhu S; Pecorelli S; Parham GP; Cannon MJ
    Clin Cancer Res; 2001 Mar; 7(3 Suppl):804s-810s. PubMed ID: 11300476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T-cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer.
    Chan PK; Liu SJ; Cheung JL; Cheung TH; Yeo W; Chong P; Man S
    J Med Virol; 2011 Jun; 83(6):1023-30. PubMed ID: 21503915
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer.
    Scholten KB; Schreurs MW; Ruizendaal JJ; Kueter EW; Kramer D; Veenbergen S; Meijer CJ; Hooijberg E
    Clin Immunol; 2005 Feb; 114(2):119-29. PubMed ID: 15639645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of cytotoxic T lymphocytes with dendritic cells transfected with human papillomavirus E6 and E7 RNA: implications for cervical cancer immunotherapy.
    Thornburg C; Boczkowski D; Gilboa E; Nair SK
    J Immunother; 2000; 23(4):412-8. PubMed ID: 10916750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7.
    Steller MA; Gurski KJ; Murakami M; Daniel RW; Shah KV; Celis E; Sette A; Trimble EL; Park RC; Marincola FM
    Clin Cancer Res; 1998 Sep; 4(9):2103-9. PubMed ID: 9748126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
    Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of human MHC-I HPV18 E6/E7-specific CD8 + T cell epitopes and generation of an HPV18 E6/E7-expressing adenosquamous carcinoma in HLA-A2 transgenic mice.
    Peng S; Xing D; Ferrall L; Tsai YC; Hung CF; Wu TC
    J Biomed Sci; 2022 Oct; 29(1):80. PubMed ID: 36224625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein.
    Nakagawa M; Kim KH; Gillam TM; Moscicki AB
    J Virol; 2007 Feb; 81(3):1412-23. PubMed ID: 17108051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cervical carcinoma cells transfected with the CD80 gene elicit a primary cytotoxic T lymphocyte response specific for HPV 16 E7 antigens.
    Kaufmann AM; Gissmann L; Schreckenberger C; Qiao L
    Cancer Gene Ther; 1997; 4(6):377-82. PubMed ID: 9408608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T-cell response to human papillomavirus type 58 L1, E6, And E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer.
    Chan PK; Liu SJ; Cheung TH; Yeo W; Ngai SM; Cheung JL; Chong P; Man S
    Clin Vaccine Immunol; 2010 Sep; 17(9):1315-21. PubMed ID: 20668141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells.
    Sima N; Wang S; Wang W; Kong D; Xu Q; Tian X; Luo A; Zhou J; Xu G; Meng L; Lu Y; Ma D
    Gynecol Oncol; 2007 Aug; 106(2):299-304. PubMed ID: 17586029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human papillomavirus type 33 E7 peptides presented by HLA-DR*0402 to tumor-infiltrating T cells in cervical cancer.
    Höhn H; Pilch H; Günzel S; Neukirch C; Freitag K; Necker A; Maeurer MJ
    J Virol; 2000 Jul; 74(14):6632-6. PubMed ID: 10864677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein.
    Street MD; Doan T; Herd KA; Tindle RW
    Immunology; 2002 Aug; 106(4):526-36. PubMed ID: 12153516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III.
    Nimako M; Fiander AN; Wilkinson GW; Borysiewicz LK; Man S
    Cancer Res; 1997 Nov; 57(21):4855-61. PubMed ID: 9354449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7.
    Nonn M; Schinz M; Zumbach K; Pawlita M; Schneider A; Dürst M; Kaufmann AM
    J Cancer Res Clin Oncol; 2003 Sep; 129(9):511-20. PubMed ID: 12905010
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
    Rice AE; Latchman YE; Balint JP; Lee JH; Gabitzsch ES; Jones FR
    Cancer Gene Ther; 2015 Sep; 22(9):454-62. PubMed ID: 26337747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of the impact on T- and B- cell epitopes of human papillomavirus type-16 E6 and E7 variant in Southwest China.
    Chenzhang Y; Wen Q; Ding X; Cao M; Chen Z; Mu X; Wang T
    Immunol Lett; 2017 Jan; 181():26-30. PubMed ID: 27693214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.